A tiny drop of blood may soon help doctors detect serious diseases much earlier than before. In a new study, researchers from Peking University (PKU) in China developed an innovative technology that can trace the source of disease signals using only a very small amount of blood.
The research was published on March 4, 2026, in the scientific journal Nature and was led by Professor He Aibin from the College of Future Technology at PKU and Professor Jing Hongmei from the Department of Hematology at Peking University Third Hospital.
Doctors have long been interested in a method called liquid biopsy. Unlike traditional biopsies, which require removing tissue from the body through surgery or needles, liquid biopsies analyze blood samples to look for signs of disease.
This method is less invasive, safer, and easier for patients. In theory, a simple blood test could detect cancer or other diseases early, track how a disease changes, and monitor whether treatment is working.
However, current liquid biopsy technologies still have important limitations. While they can detect fragments of DNA or other molecules released by damaged or diseased cells, they often cannot clearly identify where these signals come from in the body.
For example, if abnormal genetic material is found in the blood, doctors may know that something is wrong, but they may not know which organ or tissue is responsible. This lack of precision can make diagnosis more difficult.
To address this problem, the PKU research team developed a new platform called cf‑EpiTracing. The name stands for “cell‑free epigenetic tracing.” The technology focuses on tiny biological fragments circulating in the blood that come from cells throughout the body. These fragments contain epigenetic information, which refers to chemical marks that control how genes are turned on or off in different cell types.
Each tissue in the body has its own epigenetic signature. By studying these signatures, scientists can determine where the fragments in the blood originally came from. The cf‑EpiTracing platform captures these epigenetic patterns and analyzes them in great detail, allowing researchers to trace disease signals back to specific tissues.
One of the most remarkable features of this technology is how little blood it needs. The system can work with just 50 microliters of plasma, which is roughly the size of a single drop of blood. This makes the test potentially faster, easier, and more comfortable for patients compared with existing diagnostic methods.
The technology works by detecting special structures called cell‑free chromatin. Chromatin is the material that packages DNA inside cells. When cells die or release fragments into the bloodstream, small pieces of chromatin can circulate in the blood. These fragments still carry chemical marks known as histone modifications, which provide clues about the cell type they came from.
Using advanced sequencing methods, the researchers collected information about several types of these chemical marks. They then applied machine learning algorithms to analyze the complex patterns. Machine learning is a type of artificial intelligence that allows computers to recognize patterns in large datasets and make predictions based on them.
In tests involving colorectal cancer detection, the results were very promising. The cf‑EpiTracing system combined several epigenetic features and used machine learning to identify disease signals.
In the training group of samples, the method achieved an accuracy rate of 97.6 percent. When tested in a separate validation group, which helps confirm that results are reliable, the accuracy remained very high at 92.2 percent.
These results suggest that the technology may be able to detect colorectal cancer with high reliability, even using extremely small blood samples. Early detection of colorectal cancer is especially important because treatment is much more effective when the disease is discovered in its early stages.
The researchers also made an important discovery related to lymphoma, a type of cancer that affects the lymphatic system and blood cells. They studied patients with diffuse large B‑cell lymphoma, one of the most common forms of lymphoma. Using the cf‑EpiTracing system, they detected unusually strong signals from CD34‑positive cells in the patients’ blood plasma.
CD34‑positive cells are often associated with bone marrow activity. The presence of strong signals from these cells may indicate that the disease has involved the bone marrow or that it is behaving more aggressively. This insight could help doctors better classify lymphoma subtypes and choose more appropriate treatment strategies for individual patients.
Beyond these findings, the research team believes that the technology could become even more powerful in the future. The next step may involve combining cf‑EpiTracing with other types of cell‑free biological information found in blood. These include DNA mutations, DNA methylation patterns, and the three‑dimensional structure of chromatin.
By integrating multiple types of biological data, scientists could create a “multi‑omic” diagnostic system. This approach may allow doctors to detect diseases earlier, track how they progress, and observe how different cell types change during treatment.
Such systems could eventually monitor many diseases, including cancers, autoimmune conditions, and other complex disorders.
Looking at the study overall, the findings represent a major step forward in non‑invasive medical diagnostics. The ability to trace disease signals from just a drop of blood could make testing faster, cheaper, and more widely available.
However, it is important to note that the technology is still in the research stage. Larger clinical studies will be needed to confirm how well it works across diverse patient populations.
If future studies confirm these early results, cf‑EpiTracing could transform how doctors diagnose and monitor disease. Instead of waiting for symptoms to appear or performing invasive tissue biopsies, physicians may one day detect disease through routine blood tests long before serious damage occurs.
In summary, the new technology offers an exciting glimpse into the future of medicine. By combining epigenetic analysis with artificial intelligence, scientists may be able to unlock detailed information hidden in a tiny drop of blood. This approach could lead to earlier diagnoses, more precise treatments, and better outcomes for patients around the world.
If you care about medicine, please read studies that vitamin D could help lower the risk of autoimmune diseases, and drug for inflammation may stop spread of cancer.
For more health information, please see recent studies about which drug can harm your liver most, and results showing this drug can give your immune system a double boost against cancer.
Copyright © 2026 Knowridge Science Report. All rights reserved.
